A recent treatment for human African trypanosomiasis, commonly known as sleeping sickness, has received approval from the European Medicines Agency (EMA). This development offers renewed hope for patients in affected regions, particularly in the Democratic Republic of Congo (DRC), where the disease remains a significant public health challenge. The approval follows years of clinical trials, … Read more
Source link